SCHEMBL5847385

SCHEMBL5847385

NS(=O)(=O)c1ccc2c(c1)CC[C@H](C(=O)O)O2

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.50
OPRK1 P41145 1/20 0.50
CA1 P00915 9/20 0.46
CA2 P00918 9/20 0.46
CA12 O43570 9/20 0.46
CA7 P43166 9/20 0.46
CA14 Q9ULX7 9/20 0.46
CA9 Q16790 6/20 0.46
STS P08842 1/20 0.41
PPARG P37231 2/20 0.41
PPARA Q07869 1/20 0.41
CYP4F2 P78329 3/20 0.41
CYP4A11 Q02928 3/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
GAPDH P04406 1/20 0.39
HSPA1A P0DMV8 1/20 0.39
PTPN7 P35236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5847391 1.00 CYP2D6 (0.50) CYP2D6OPRK1CA1CA2CA12
SCHEMBL5847381 1.00 CYP2D6 (0.50) CYP2D6OPRK1CA1CA2CA12
SCHEMBL5847215 0.81 SMN1; SMN2 (0.51)
SCHEMBL5847221 0.81 SMN1; SMN2 (0.51)
SCHEMBL5847218 0.81 SMN1; SMN2 (0.51)
SCHEMBL5846709 0.80 GAA (0.48) CYP2D6OPRK1PPARGPPARACYP4F2
SCHEMBL5846816 0.80 GAA (0.48) CYP2D6OPRK1PPARGPPARACYP4F2
SCHEMBL5847229 0.80 GAA (0.48) CYP2D6OPRK1PPARGPPARACYP4F2
SCHEMBL5846797 0.80 CYP4F2 (0.44) PPARGPPARACYP4F2CYP4A11NFKB1
SCHEMBL4672071 0.80 CYP4F2 (0.44) PPARGPPARACYP4F2CYP4A11NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034051-B2 Fused bicyclic carboxamide derivatives and methods of their use ADOLOR CORPORATION (US) 2006-04-25 US disclosed
WO-2005023799-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-03-17 WO disclosed
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use CUBIST PHARMACEUTICALS, INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054630-A1 Fused bicyclic carboxamide derivatives and methods of their use PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 CYP2D6 44/4885OPRK1 268/4885CA1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.